Daily Medication Pearl: Symbyax (Olanzapine and Fluoxetine Hydrochloride)

Article

Symbyax combines olanzapine, an atypical antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive episodes associated with bipolar I disorder in adults.

Medication Pearl of the Day: Symbyax (Olanzapine and Fluoxetine Hydrochloride)

Indication: Symbyax combines olanzapine, an atypical antipsychotic, and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive episodes associated with bipolar I disorder in adults.

Insights:

  • Dosing: Once daily in the evening, generally beginning with 6 mg/25 mg
  • Dosage forms: Capsules: 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, and 12 mg/50 mg
  • Adverse events: Most common adverse reactions (≥5% and at least twice that for placebo) are blurred vision,, disturbance in attention, dry mouth, fatigue, hypersomnia, increased appetite, peripheral edema, sedation, somnolence, tremors, and weight gain.
  • Mechanism of action: Although the exact mechanism of SYMBYAX is unknown, it has been proposed that the activation of 3 monoaminergic neural systems (dopamine, norepinephrine, and serotonin, ) are responsible for its enhanced antidepressant effect.

Source:

Symbyax Label (fda.gov)

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Image credit: photoopus | stock.adobe.com Borderline personality disorder (BPD) Mental Illness. Banner and Concept Image.
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Image credit: Melita - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.